Athira Pharma (LONA) Stock Price, News & Analysis

Company Overview

Athira Pharma, Inc. is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system. Fosgonimeton has advanced through Phase 1 and Phase 2 clinical trials, where it has been evaluated for safety, tolerability and preliminary efficacy in patients with mild to moderate Alzheimer’s disease and other forms of cognitive impairment. In addition to ATH‐1017, the company is exploring follow‐on small‐molecule candidates designed to target related pathways and broaden the potential therapeutic impact across multiple neurodegenerative indications.

Athira Pharma went public in 2019 and is traded on the Nasdaq under the symbol ATHA. The company conducts clinical studies in the United States and Europe in collaboration with academic research centers and contract research organizations. Leadership has included key figures from both the biotech and neuroscience research communities, with a management team experienced in drug development, clinical operations and regulatory affairs. Athira continues to engage with strategic partners to support its mission of bringing novel, disease‐modifying treatments to patients suffering from progressive neurological disorders.

Key Stats

• Today's Range: $8.96 to $9.39
• 50-Day Range: $7.88 to $11.26
• 52-Week Range: $3.24 to $14.21
• Volume: 5,900 shs
• Average Volume: 53,922 shs
• Market Capitalization: $88.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Hold

Athira Pharma Stock Analysis - MarketRank™

Athira Pharma scored higher than 70% of companies evaluated by MarketBeat, and ranked 172nd out of 845 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Athira Pharma has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Athira Pharma has a consensus price target of $15.00, representing about 59.7% upside from its current price of $9.39.

Amount of Analyst Coverage

Athira Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Athira Pharma are expected to grow in the coming year, from ($3.12) to ($1.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Athira Pharma is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Athira Pharma is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Athira Pharma has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.74% of the float of Athira Pharma has been sold short.

Short Interest Ratio / Days to Cover

Athira Pharma has a short interest ratio ("days to cover") of 2.94, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Athira Pharma has recently decreased by 8.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Athira Pharma does not currently pay a dividend.

Dividend Growth

Athira Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Athira Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.73% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 7/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LONA
• Previous Symbol: NASDAQ:ATHA
• CIK: 1620463
• Web: athira.com
• Phone: 425-620-8501
• Fax: N/A
• Employees: 40
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Athira Pharma: $15.00
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +59.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$105.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -381.01%
• Return on Assets: -225.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.38
• Quick Ratio: 10.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.98 per share
• Price / Book: 3.15

Miscellaneous

• Outstanding Shares: 9,390,000
• Free Float: 6,977,000
• Market Cap: $88.17 million
• Optionable: No Data
• Beta: 2.01